GlassScriptPhysician profile
Briana E Disilvio
NPI 1134569973
$203,545.03
in general payments reported to CMS, 2019-2025
18 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $177 · 2021: $16K · 2022: $18K · 2023: $40K · 2024: $34K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Honoraria: $22K · Food and Beverage: $7,100 · Travel and Lodging: $3,813 · Consulting Fee: $1,950 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $134,865.00 |
| Honoraria | $21,800.00 |
| Food and Beverage | $7,099.66 |
| Travel and Lodging | $3,813.03 |
| Consulting Fee | $1,950.00 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $115,991.63 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $30,755.50 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $29,363.53 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Verona Pharma, INC. | $25,957.11 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $252.57 | 2022-2025 | Dupixent |
| Pulmonx Corporation | $239.46 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Genzyme Corporation | $230.12 | 2021-2023 | |
| Insmed, INC. | $203.52 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $137.50 | 2025 | Dupixent |
| Genentech USA, INC. | $99.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Boston Scientific Corporation | $56.27 | 2020 | |
| United Therapeutics Corporation | $53.52 | 2025 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $38.14 | 2021 | |
| Mindray Ds USA, INC. | $29.59 | 2023 | Te7 Max, Te X |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $26.87 | 2024 | Smartvest |
| Vapotherm INC | $13.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briana Disilvio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.